Expansion Opportunities in Lung and Liver
RvE1 preclinical proof of concept in pulmonary fibrosis and liver injury
Pulmonary Fibrosis
Bleomycin lung fibrosis
Collagen deposition
Lung stiffness
RvE1 dosed after fibrosis onset (days 14–20) reduced lung collagen and lung stiffness.
C57BL/6J male mice, n = 6–10 per group, RvE1 4 µg/kg i.p. once daily days 14–20; *p < 0.05 vs BLM. BLM = bleomycin. Antifibrotic effect in this model reported in Ohomori et al., Am J Respir Crit Care Med 2010;181:A3566 (Fukunaga K, ATS 2008); chart data courtesy of Prof. Koichi Fukunaga, Keio University.
Liver Fibrosis
DEN-induced liver injury
Tissue architecture
Inflammation
RvE1 preserved hepatic architecture and reduced inflammation in DEN-induced liver injury.
Male Sprague-Dawley rats, DEN i.p. weekly × 4 weeks, RvE1 4 µg/kg i.p. twice weekly, n = 6–9 per group; *p < 0.05 vs DEN. Rodríguez et al., Int J Mol Sci 2020;21:8827.
Partner with Thetis
TP-317 in fibrotic diseases is available for partnering alongside the IBD program.